Tags : Aileron Therapeutics


Aileron Therapeutics & Dana-Farber/Boston Children’s Cancer and Blood Disorders Center

Shots: The agreement involves onset of P-I trial including Pediatric Patients with solid tumors & acute leukemia receiving ALRN-6924 as a monotx & in combination with cytarabine With the above two studies, an additional study will be initiated involving biomarker with the approach to improve response rates ALRN-6924 is a novel dual inhibitor of MDM2/MDMX […]Read More